This page shows what was measured, who it was measured in, and what that does not settle.
What Nogapendekin alfa Inbakicept-Pmln does in the body
BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
From the FDA-approved label: Nogapendekin alfa inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4 + and CD8 + T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8 + , and memory T cells without proliferation of immuno-suppressive Treg cells.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 7TK323DLA0 · read 2026-08-29
Where each sentence above came from
The recorded explanation is written in label language rather than for a beginner. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 126 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 37 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Healthy ageing
28 day all cause mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
… Waiting for a reviewer
1 registered study measure of this kind. No reviewed result yet.
∅ Nothing in the sources checked
No registered study lists a performance measure for this goal.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
The expansion of rare persisting transferred T-cell receptor therapy
✗ The study did not show it
Who was studied
NCT07261657
How many people
8
Study design
Early phase 1
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravesical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 1 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.7 registered measures of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.3 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
maximum observed concentration
heart rate
blood pressure
Meaningful
Things that change how a life goes, not only a number.
kaplan meier estimate of leukemia free survival rate
progression free survival
relapse free survival
progression free survival by recist v1 1
overall survival
event free survival
28 day all cause mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (27)
dose limiting toxicity events
maximal tolerated or tested dose of ciml nk cells
dose limiting toxicity
treatment emergent adverse events
overall response rate
objective response rate
complete response
dose limiting toxicities
adverse events
objective response rate by recist version 1 1
objective response rate by irrc
orr by immune related response criteria
treatment emergent adverse events and serious aes
pathological complete response rate
half life
apparent volume of distribution
apparent clearance
safety
12 lead electrocardiogram
incidence of adverse events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of ANKTIVA in pediatric patients have not been established.”
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-30
On older people, the label states: “Clinical studies of ANKTIVA did not include sufficient numbers of younger adult patients to determine if patients 65 years of age and older respond differently than younger adult patients.”
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Systemic exposure of nogapendekin alfa inbakicept-pmln following intravesical administration of the approved dosage of ANKTIVA was below the limit of quantitation [see Clinical Pharmacology 12.3 )] .”
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-30
On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Based on its mechanism of action, ANKTIVA may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] .”
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravesical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as solution, given by the intravesical route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravesical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 product lists this as an active ingredient in the United States drug directory. 1 of them contain it and nothing else.
FDA National Drug Code directory · 81481-803 · read 2026-08-29
They are sold as solution, taken intravesical.
FDA National Drug Code directory · 81481-803 · read 2026-08-29
The regulator's established pharmacologic class for it is interleukin-15 receptor agonist [epc] and interleukin-15 receptor agonists [moa].
FDA National Drug Code directory · 81481-803 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-29
13 marketed supplement labels list this ingredient, classed as botanical, fat/fatty acid and other combinations.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
ANKTIVA is intravesical at 3 DOSAGE FORMS AND STRENGTHS 400 mcg/0.4 mL, clear to slightly opalescent and colorless to slightly yellow solution in single-dose vials for intravesical instillation after dilution. 400 mcg/0.4 mL, clear to slightly op…, recorded as fda label in effect 2025-06-24 in the United States.
US prescribing information · eae31db8-3e7a-d9e0-708d-74419d1b50ff · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
Evidence on this page does not automatically apply to this one.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Nogapendekin alfa Inbakicept-Pmln studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Nogapendekin alfa Inbakicept-Pmln are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
7TK323DLA0
RxNorm concept
2682684
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was BLA761336, approved 20240422 to ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (9)
Q1
What did Nogapendekin alfa Inbakicept-Pmln's largest trial (507 people) and its longest (12 years) measure?
507 people in Nogapendekin alfa Inbakicept-Pmln's largest registered study, 12 years in its longest registered window, measuring 28-day all-cause mortality. ClinicalTrials.gov · 2026-09-01
63 phase2, 44 phase1, 3 phase3, 2 na or unstated, 1 early phase1; NCT03022825; 2029-03-01; no ageing endpoint recorded. Last human test completed 2026, NCT04847466.
Interpretation These counts include studies where Nogapendekin alfa Inbakicept-Pmln was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
63
phase1
44
phase3
3
na or unstated
2
early phase1
1
Last recorded human testNCT04847466
2026-01-06
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Nogapendekin alfa Inbakicept-Pmln shown lifespan?
safety (1), accrual/recruitment (7), funding/business (2) and other (29): Nogapendekin alfa Inbakicept-Pmln's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Insufficient funding/staff"; 39 of 80 registered studies
Show the evidence
Trial
NCT01898793
terminated; "Insufficient funding/staff"
NCT02099539
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
NCT02384954
terminated; "Change in drug product development strategy."
NCT03003728
withdrawn; "Withdrawal of study support"
NCT03127098
terminated; "The study was terminated before any dose escalation occurred in order to pursue other studies designed to more extensively evaluate the combination of ETBX-011 and N-803 along with other immunotherapy agents."
NCT03136406
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
14 further recorded trials
NCT03167164
withdrawn; "Trial not initiated"
NCT03167177
withdrawn; "Trial not initiated"
NCT03169738
withdrawn; "Trial not initiated"
NCT03169764
withdrawn; "Trial not initiated"
NCT03169777
withdrawn; "Trial not initiated"
NCT03169790
withdrawn; "Trial not initiated"
NCT03175666
withdrawn; "Trial not initiated"
NCT03197571
withdrawn; "Trial not initiated"
NCT03197584
withdrawn; "Trial not initiated"
NCT03329248
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
NCT03365661
withdrawn; "Sponsor halted study."
NCT03387085
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
NCT03387098
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
NCT03387111
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Could one person measure Nogapendekin alfa Inbakicept-Pmln's effect on dose limiting toxicity events?
Dose limiting toxicity events: measured in Nogapendekin alfa Inbakicept-Pmln's trials.
Interpretation dose limiting toxicity events is the recorded endpoint.
Show the evidence
biomarkers
dose limiting toxicity events; 2026-09-01
maximal tolerated or tested dose of ciml nk cells; 2026-09-01
dose limiting toxicity; 2026-09-01
treatment emergent adverse events; 2026-09-01
overall response rate; 2026-09-01
objective response rate; 2026-09-01
14 more recorded rows
biomarkers
kaplan meier estimate of leukemia free survival rate; 2026-09-01
biomarkers
complete response; 2026-09-01
biomarkers
dose limiting toxicities; 2026-09-01
biomarkers
adverse events; 2026-09-01
biomarkers
objective response rate by recist version 1 1; 2026-09-01
biomarkers
objective response rate by irrc; 2026-09-01
biomarkers
orr by immune related response criteria; 2026-09-01
biomarkers
treatment emergent adverse events and serious aes; 2026-09-01
biomarkers
pathological complete response rate; 2026-09-01
biomarkers
progression free survival; 2026-09-01
biomarkers
relapse free survival; 2026-09-01
biomarkers
progression free survival by recist v1 1; 2026-09-01
biomarkers
half life; 2026-09-01
biomarkers
apparent volume of distribution; 2026-09-01
human trials at or under30
57
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT03003728; PHASE2; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q5
Which of 12 lead electrocardiogram, 28 day all cause mortality and adverse events did Nogapendekin alfa Inbakicept-Pmln's trials measure?
12 lead electrocardiogram, 28 day all cause mortality and adverse events lead 37 outcome terms across Nogapendekin alfa Inbakicept-Pmln's trials. ClinicalTrials.gov · 2026-09-01
"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation"; n 60; "Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)"; 2028-02-13
NCT03022825
"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer"; n 190; "Complete Response"; 2029-03-01
NCT04340596
"Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption"; n 118; "Occurrence of a Grade ≥3 adverse event (AE) that is at least possibly related to N-803, as judged by the Clinical Management Committee (CMC)"; 2026-12-30
NCT04390399
"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer"; n 328; "Progression Free Survival (PFS)"; 2026-05-31
NCT04505501
"Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection"; n 14; "Rate of occurrence of ≥ grade 3 adverse events determined to be related (Safety)"; 2025-06-30
NCT04898543
"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors"; n 50; "Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to…"; 2026-05-31
14 further recorded trials
NCT05096663
"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)"; n 82; "Overall survival"; 2027-12-01
NCT05618925
"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma"; n 20; "Primary Outcome Measures"; 2027-03-15
NCT06061809
"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma"; n 34; "Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)"; 2030-12-31
NCT06149481
"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)"; n 60; "Phase I: Safety profiles of the IO regimens consisting of retifanlimab, TriAdeno vaccine, N-803 (A1), and retifanlimab, TriAdeno vaccine, N-803, SX-682 (A2) in participants with metastatic colorectal cancer"; 2030-10-31
NCT06161545
"Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma"; n 40; "pTR rate (viable tumor in 50% or less of the surgically resected primary tumor bed)"; 2028-12-01
NCT06239220
"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC"; n 25; "Objective Response Rate (ORR)"; 2027-03-31
NCT06253494
"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer"; n 60; "Phase I: Estimate recommended RP2D of pembrolizumab, lenvatinib, N-803, and AdHER2DC vaccine in participants with HER2 positive endometrial cancer"; 2028-12-31
NCT06710288
"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer"; n 20; "Evaluate Progression Free Survival (PFS)"; 2027-05
NCT06745908
"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In"; n 507; "Compare Overall Survival between the experimental and control arms"; 2029-01
NCT06829823
"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer"; n 20; "Efficacy of Arms A and B at Month 3 and Month 6"; 2029-11
NCT06956547
"Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy"
NCT07108036
"A Study to Assess Anktiva in Patients With Long Covid-19."; n 20; "Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration."; 2026-10
NCT07123727
"A Study to Examine Anktiva for the Treatment of COVID-19."; n 40; "Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration."; 2026-07
NCT07145164
"Interleukin-15 to Promote Post-ART Control of HIV"; n 20; "Safety - Solicited Adverse Events"; 2028-12
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which running trial of Nogapendekin alfa Inbakicept-Pmln could settle lifespan?
NCT04390399 measures Progression Free Survival (PFS), reading out 2026-05-31.
8 open trials; n 328; "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer"
Show the evidence
Trial
NCT04390399
"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer"; n 328; "Progression Free Survival (PFS)"; 2026-05-31
NCT06710288
"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer"; n 20; "Evaluate Progression Free Survival (PFS)"; 2027-05
NCT07578558
"NAI for Sepsis With Persistent Lymphopenia"; n 50; "28-day all-cause mortality rate"; 2027-10-04
NCT05096663
"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)"; n 82; "Overall survival"; 2027-12-01
NCT07783789
"NAI (Nogapendekin Alfa Inbakicept) Plus Standard of Care in Critically Ill Adults With Sepsis"; n 49; "28-Day Survival Rate"; 2027-12-13
NCT02782546
"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation"; n 60; "Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)"; 2028-02-13
2 further recorded trials
NCT06745908
"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In"; n 507; "Compare Overall Survival between the experimental and control arms"; 2029-01
NCT07355205
"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer"; n 26; "Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)"; 2032-07-31
Q8
Which 3 trials of Nogapendekin alfa Inbakicept-Pmln posted no result?
Posted no result
3 of 3 completed trials
Registrations
NCT02559674, NCT02191098 and NCT06040918
Completion dates
oldest 2018-02-21; newest 2024-09-03
Show the evidence
Trial
NCT02559674
2018-02-21
NCT02191098
2019-09-09
NCT06040918
2024-09-03
Q9
At the median, Nogapendekin alfa Inbakicept-Pmln's trials enrolled 10 people — anything larger?
Median enrolment
10
Largest enrolment
507
Registered trials counted
79
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 4 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.